Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Von Willebrand factor, ADAMTS13 activity, TNF-α and their relationships in patients with chronic kidney disease.

Shen L, Lu G, Dong N, Jiang L, Ma Z, Ruan C.

Exp Ther Med. 2012 Mar;3(3):530-534. Epub 2011 Dec 23.

2.

Influences of ABO blood group, age and gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13 levels in a Chinese population.

Wang Z, Dou M, Du X, Ma L, Sun P, Cao H, Ye S, Jiang P, Liu F, Lin F, Zhang R, Li C.

PeerJ. 2017 Mar 30;5:e3156. doi: 10.7717/peerj.3156. eCollection 2017.

3.

Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.

Qu L, Jiang M, Qiu W, Lu S, Zhao Y, Xia L, Ruan C, Zhao Y.

Clin Appl Thromb Hemost. 2016 Apr;22(3):252-9. doi: 10.1177/1076029615583347. Epub 2015 Apr 27.

PMID:
25916953
4.

Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases.

Lu GY, Shen L, Wang ZY, Guo XF, Bai X, Su J, Ruan CG.

Chin Med J (Engl). 2008 Jan 20;121(2):133-6.

PMID:
18272039
5.

Von Willebrand Factor, ADAMTS13 and D-Dimer Are Correlated with Different Levels of Nephropathy in Type 1 Diabetes Mellitus.

Domingueti CP, Dusse LM, Fóscolo RB, Reis JS, Annichino-Bizzacchi JM, Orsi FL, Mazetto Bde M, Carvalho Md, Gomes KB, Fernandes AP.

PLoS One. 2015 Jul 13;10(7):e0132784. doi: 10.1371/journal.pone.0132784. eCollection 2015.

6.

Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study.

Sonneveld MA, Franco OH, Ikram MA, Hofman A, Kavousi M, de Maat MP, Leebeek FW.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2446-2451. Epub 2016 Oct 13.

PMID:
27737864
7.

Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia.

Ishikawa M, Uemura M, Matsuyama T, Matsumoto M, Ishizashi H, Kato S, Morioka C, Fujimoto M, Kojima H, Yoshiji H, Tsujimoto T, Takimura C, Fujimura Y, Fukui H.

Alcohol Clin Exp Res. 2010 Feb;34 Suppl 1:S25-33. doi: 10.1111/j.1530-0277.2008.00850.x. Epub 2009 Dec 16.

PMID:
19094193
8.

Alteration of circulatory platelet microparticles and endothelial microparticles in patients with chronic kidney disease.

Lu GY, Xu RJ, Zhang SH, Qiao Q, Shen L, Li M, Xu DY, Wang ZY.

Int J Clin Exp Med. 2015 Sep 15;8(9):16704-8. eCollection 2015.

9.

Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.

Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y.

Heart Vessels. 2008 Sep;23(5):301-7. doi: 10.1007/s00380-008-1053-x. Epub 2008 Sep 20.

PMID:
18810578
10.

Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.

Matsuyama T, Uemura M, Ishikawa M, Matsumoto M, Ishizashi H, Kato S, Morioka C, Fujimoto M, Kojima H, Yoshiji H, Takimura C, Fujimura Y, Fukui H.

Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S27-35.

PMID:
17331163
11.

Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.

Mazur P, Plicner D, Zdziarska J, Sadowski J, Undas A.

Eur J Cardiothorac Surg. 2014 Feb;45(2):e26-32. doi: 10.1093/ejcts/ezt527. Epub 2013 Dec 17.

PMID:
24351199
12.

Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute cholangitis.

Takaya H, Kawaratani H, Kubo T, Seki K, Sawada Y, Kaji K, Okura Y, Takeda K, Kitade M, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.

Hepatol Res. 2017 Jun 19. doi: 10.1111/hepr.12926. [Epub ahead of print]

PMID:
28628948
13.

von Willebrand Factor, ADAMTS13 Activity, and Decline in Kidney Function: A Population-Based Cohort Study.

Sedaghat S, de Vries PS, Boender J, Sonneveld MA, Hoorn EJ, Hofman A, de Maat MP, Franco OH, Ikram MA, Leebeek FW, Dehghan A.

Am J Kidney Dis. 2016 Nov;68(5):726-732. doi: 10.1053/j.ajkd.2016.05.032. Epub 2016 Aug 3.

PMID:
27497525
14.

Levels of von Willebrand factor antigen and von Willebrand factor cleaving protease (ADAMTS13) activity predict clinical events in chronic heart failure.

Gombos T, Makó V, Cervenak L, Papassotiriou J, Kunde J, Hársfalvi J, Förhécz Z, Pozsonyi Z, Borgulya G, Jánoskuti L, Prohászka Z.

Thromb Haemost. 2009 Sep;102(3):573-80. doi: 10.1160/TH09-01-0036.

PMID:
19718479
15.

[The association of von Willebrand factor and von Willebrand factor-cleaving protease in systemic lupus erythematosus].

Lu GY, Guo XF, Wang ZY, Bai X, Su J, Ruan CG.

Zhonghua Nei Ke Za Zhi. 2006 Jan;45(1):42-4. Chinese.

PMID:
16624087
16.
17.

Effect of Vitamin D Status on Von Willebrand Factor and ADAMTS13 in Diabetic Patients on Chronic Hemodialysis.

Cohen-Hagai K, Rashid G, Einbinder Y, Ohana M, Benchetrit S, Zitman-Gal T.

Ann Lab Med. 2017 Mar;37(2):155-158. doi: 10.3343/alm.2017.37.2.155.

18.

Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke.

McCabe DJ, Murphy SJ, Starke R, Harrison P, Brown MM, Sidhu PS, Mackie IJ, Scully M, Machin SJ.

J Neurol Sci. 2015 Jan 15;348(1-2):35-40. doi: 10.1016/j.jns.2014.10.035. Epub 2014 Oct 31.

PMID:
25498844
19.

Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia.

Molvarec A, Rigó J Jr, Bõze T, Derzsy Z, Cervenak L, Makó V, Gombos T, Udvardy ML, Hársfalvi J, Prohászka Z.

Thromb Haemost. 2009 Feb;101(2):305-11.

PMID:
19190814
20.

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW.

Stroke. 2006 Nov;37(11):2672-7. Epub 2006 Sep 21.

Supplemental Content

Support Center